Back to Authors

Kuruvilla, Deena E.

https://orcid.org/0000-0002-1997-5663

Mayo Clinic

Westport Headache Institute

Citations 3

A Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM) (P11-2.005)
Kuruvilla, Deena E. , Starling, Amaal J. , Tepper, Stewart J. , Mann, J. John , Panza, Gregory A. , Johnson, Michael L.

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.2994 Get It

The Sphenopalatine Ganglion: Anatomy, Pathophysiology, and Therapeutic Targeting in Headache
Robertson, Carrie E. , Kaplan, Eugene D. , Kuruvilla, Deena E. , Blumenfeld, Andrew , Berliner, Randall, Rosen, Noah , Duarte, Robert , Vidwan, Jaskiran, Halker, Rashmi, Gill, Nicole, Halker, Rashmi B, Robbins, Matthew S. , Ailani, Jessica , Charleston, Larry , Ashkenazi, Avi , Robertson, Carrie E

Headache: The Journal of Head and Face Pain | November 30, 2015 | Volume: 56 | Issue: 2 | Pages: 240-258

10.1111/head.12729 Get It

The sphenopalatine ganglion (SPG) has attracted the interest of practitioners treating head and face pain for over a century because of its anatomical connections and role in the trigemino‐autonomic reflex. In this review, we discuss the anatomy of the SPG, as well as what is known about its role in the pathophysiology of headache disorders, including cluster headache and migraine. We then address various therapies that target the SPG, including intranasal medication delivery, new SPG blocking catheter devices, neurostimulation, chemical neurolysis, and ablation procedures.
Trigger Point Injections for Headache Disorders: Expert Consensus Methodology and Narrative Review
Kuruvilla, Deena E. , Blumenfeld, Andrew , Sorrell, Michael R., Robertson, Carrie E. , Grosberg, Brian M. , Bender, Steven D. , Napchan, Uri, Robbins, Matthew S. , Charleston, Larry , Ashkenazi, Avi , Robertson, Carrie E

Headache: The Journal of Head and Face Pain | August 28, 2014 | Volume: 54 | Issue: 9 | Pages: 1441-1459

10.1111/head.12442 Get It

Objective/Background To review the existing literature and describe a standardized methodology by expert consensus for the performance of trigger point injections ( TPIs ) in the treatment of headache disorders. Despite their widespread use, the efficacy, safety, and methodology of TPIs have not been reviewed specifically for headache disorders by expert consensus. Methods The Peripheral Nerve Blocks and Other Interventional Procedures Special Interest Section of the A merican H eadache S ociety over a series of meetings reached a consensus for nomenclature, indications, contraindications, precautions, procedural details, outcomes, and adverse effects for the use of TPIs for headache disorders. A subcommittee of the Section also reviewed the literature. Results Indications for TPIs may include many types of episodic and chronic primary and secondary headache disorders, with the presence of active trigger points ( TPs ) on physical examination. Contraindications may include infection, a local open skull defect, or an anesthetic allergy, and precautions are necessary in the setting of anticoagulant use, pregnancy, and obesity with unclear anatomical landmarks. The most common muscles selected for TPIs include the trapezius, sternocleidomastoid, and temporalis, with bupivacaine and lidocaine the agents used most frequently. Adverse effects are typically mild with careful patient and procedural selection, though pneumothorax and other serious adverse events have been infrequently reported. Conclusions When performed in the appropriate setting and with the proper expertise, TPIs seem to have a role in the adjunctive treatment of the most common headache disorders. We hope our effort to characterize the methodology of TPIs by expert opinion in the context of published data motivates the performance of evidence‐based and standardized treatment protocols.